Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified Clinical Trials

7 clinical trials for Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified across international registries, including 5 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma — RECRUITING · PHASE2
• Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma — RECRUITING · PHASE2
• Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma — RECRUITING · PHASE1
• Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma — RECRUITING · PHASE2
• Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy — RECRUITING · PHASE2
• Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
• TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2

Refine this search